These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10416741)

  • 1. First person account: talking through medication issues: one family's experience.
    Mann SB
    Schizophr Bull; 1999; 25(2):407-9. PubMed ID: 10416741
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 3. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia.
    Barnes TR; Liddle PF; Curson DA; Patel M
    Br J Psychiatry Suppl; 1989 Nov; (7):99-103. PubMed ID: 2575915
    [No Abstract]   [Full Text] [Related]  

  • 4. [Psychopathology and cognitive disorders in chronic schizophrenic patients with tardive dyskinesia].
    Kaiser W
    Nervenarzt; 1989 Apr; 60(4):206-12. PubMed ID: 2566936
    [No Abstract]   [Full Text] [Related]  

  • 5. The prevalence of tardive dystonia in patients with chronic schizophrenia.
    Sachdev P
    Aust N Z J Psychiatry; 1991 Dec; 25(4):446, 448. PubMed ID: 1686546
    [No Abstract]   [Full Text] [Related]  

  • 6. Subjective response to neuroleptics in schizophrenia.
    Awad AG
    Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schizophrenic patients' experiences of neuroleptic medication: a Q-methodological investigation.
    Day JC; Bentall RP; Warner S
    Acta Psychiatr Scand; 1996 May; 93(5):397-402. PubMed ID: 8792911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive performance of medicated schizophrenics with tardive dyskinesia.
    Collerton D; Fairbairn A; Britton P
    Psychol Med; 1985 May; 15(2):311-5. PubMed ID: 2862650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Schizophrenic deficit syndrome and neurologic tolerance].
    Verdoux H; Bourgeois M
    Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic.
    Pan PC; Tantam D
    Acta Psychiatr Scand; 1989 Jun; 79(6):564-70. PubMed ID: 2569803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
    Chiu H; Lau J; Lam L; Shum P
    Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic-induced emesis: a new indication for clozapine?
    Bustillo JR; Buchanan RW
    Biol Psychiatry; 1995 Aug; 38(3):194-5. PubMed ID: 7578665
    [No Abstract]   [Full Text] [Related]  

  • 14. Tardive dyskinesia and perceptual dysfunction.
    Donnelly EF; Jeste DV; Wyatt RJ
    Percept Mot Skills; 1981 Dec; 53(3):689-90. PubMed ID: 6119676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of two methods for informing schizophrenic patients about neuroleptic medication.
    Kleinman I; Schachter D; Jeffries J; Goldhamer P
    Hosp Community Psychiatry; 1993 Dec; 44(12):1189-91. PubMed ID: 7907571
    [No Abstract]   [Full Text] [Related]  

  • 16. New antipsychotic medications: do research results relate to clinical practice?
    MacEwan GW
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S75-9. PubMed ID: 7504572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia.
    Sevy S; Nathanson K; Schechter C; Fulop G
    Schizophr Bull; 2001; 27(4):643-51. PubMed ID: 11824490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients.
    Reiter S; Adler L; Angrist B; Peselow E; Rotrosen J
    J Clin Psychiatry; 1989 Jan; 50(1):26-7. PubMed ID: 2562952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First person account: what it is like to be treated like a CMI.
    Blaska B
    Schizophr Bull; 1991; 17(1):173-6. PubMed ID: 1675483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive dyskinesia, impaired recall, and informed consent.
    Ganguli R; Raghu U
    J Clin Psychiatry; 1985 Oct; 46(10):434-5. PubMed ID: 2864333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.